The effects of high-dose ibuprofen and pancreatic enzymes on the intestine of the rat

Journal of Pediatric Gastroenterology and Nutrition

Volumn 29, Issue 2, 1999, Pages 178-183

  Kimura, Robert E ^a,b   Dy, Sally Ann D ^a   Uhing, Michael R ^a   Beno, David W A ^a   Jiyamapa, Vanida A ^a   Lloyd Still, John D ^a  

^a RUSH MEDICAL COLLEGE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cystic fibrosis; Fibrosing colonopathy; Ibuprofen enteropathy; Pancreatic enzymes

Indexed keywords

I 1829; IBUPROFEN; PANCREAS ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE COURSE; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME THERAPY; FIBROSIS; INTESTINE MUCOSA PERMEABILITY; INTESTINE ULCER; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; IBUPROFEN; INTESTINAL DISEASES; INTESTINE, SMALL; LIVER; MALE; PANCREATIN; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX; ULCER;

ANIMALIA;

EID: 0033512813     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-199908000-00014     Document Type: Article

References (26)

1. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332a: 848-54.
2. Konstan MW, FitzSimmons SC. Clinical use of ibuprofen for cystic fibrosis (CF) lung disease: Data from the 1996 CF Foundation National Patient Registry. Pediatr Pulmonol 1997;14(suppl):322.
3. Oermman CM, Sockrider MM, Murry DJ. One year's experience with high dose ibuprofen therapy in CF. Pediatr Pulmonol 1996; 13(suppl):281-2.
4. Smyth RL, Van Velzen D, Smyth AL, Lloyd DA, Heaf DF. Strictures of ascending colon in cystic fibrosis and high strength pancreatic enzymes. Lancet 1994;343:85-6.
5. Lloyd-Still JD, Uhing MR, Arango V, Fusaro A, Kimura RE. The effect of intestinal permeability on pancreatic enzyme-induced enteropathy in the rat. J Pediatr Gastroenterol Nutr 1998;26:489-95.
6. Leclercq Foucart J, Forget PP, Van Cutsem JL. Lactulose-rhamnose intestinal permeability in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 1987;6:66-70.
7. Roy CC, Delage G, Fontaine A, et al. The fecal microflora and bile acids in children with cystic fibrosis. Am J Clin Nutr 1979;32: 2404-9.
8. Weber AM, Roy CC, Morin CL, Lasalle R. Malabsorption of bile acids in children with cystic fibrosis. N Engl J Med 1973;289: 1001-5.
9. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832-47.
10. Kimura RE, Arango V, Lloyd-Still JD. Indomethacin and pancreatic enzymes synergistically damage the intestine of rats. Dig Dis Sci 1998;43:2322-32.
11. Borowitz DS, Grand RJ, Durie PR. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. J Pediatr Gastroenterol Nutr 1995;127:681-4.
12. Park CM, Reid PE, Owen DA, Sanker JM, Applegarth DA. Morphological and histochemical changes in intestinal mucosa in the reserpine-treated rat model of cystic fibrosis. Exp Mol Pathol 1987;47:1-12.
13. Followill DS, Kester D, Travis EL. Histological changes in mouse colon after single- and split-dose irradiation. Radiat Res 1993;136: 280-8.
14. Melarange R, Blower P, Spangler R. Comparison of the anti-inflammatory activity and gastrointestinal irritancy of nabumetone, ibuprofen, and diclofenac in rats following chronic administration. Eur J Rheumatol Inflamm 1994;4:23-7.
15. Gutthann SP, Garcia Rodriguez LA, Raiford DS. Individual non-steroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997;8: 18-24.
16. Garcia Rodriguez LA. Nonsteroidal antiinflammatory drugs, ulcers and risk: A collaborative meta-analysis. Semin Arthritis Rheum 1997;26:16-20.
17. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis BMJ 1996;312:1563-6.
18. Brewer EJ. Nonsteroidal antiinflammatory agents. Arthritis Rheum 1977;20:513-25.
19. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-8.
20. Mulberg AE, Linz C, Bern E, Tucker L, Verhave M, Grand RJ. Identification of nonsteroidal antiinflammatory drug-induced gastroduodenal injury in children with juvenile rheumatoid arthritis. J Pediatr 1993;122:647-9.
21. Stempel DA, Miller JJ. Lymphopenia and hepatic toxicity with ibuprofen. J Pediatr 1977;90:657-8.
22. Sorensen EM, Acosta D. Relative toxicities of several nonsteroidal antiinflammatory compounds in primary cultures of rat hepatocytes. J Toxicol Environ Health 1985;16:425-40.
23. Castell JV, Larrauri A, Gomez-Lechon MJ. A study of the relative hepatotoxicity in vitro of the non-steroidal anti-inflammatory drugs ibuprofen, flurbiprofen and butibufen. Xenobiotica 1988;18: 737-45.
24. Melarange R, Moore G, Blower PR, Coates ME, Ward FW, Ronaasen V. A comparison of indomethacin with ibuprofen on gastrointestinal mucosal integrity in conventional and germ-free rats. Aliment Pharmacol Ther 1992;6:67-77.
25. Robert A, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 1977;14:333-41.
26. Davies GR, Wilkie ME, Rampton DS. Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Dig Dis Sci 1993;38:417-25.